This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition

1 hour ago 1

Jonathan Ponciano, The Motley Fool

Sun, March 22, 2026 astatine 12:56 PM CDT 4 min read

On February 17, 2026, Bridger Management disclosed successful a Securities and Exchange Commission (SEC) filing that it sold retired its full presumption successful Masimo (NASDAQ:MASI).

According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Bridger Management eliminated its full involvement successful Masimo, reducing its holdings by 47,841 shares. The fund’s quarter-end presumption successful Masimo decreased by $7.06 cardinal owed to the afloat liquidation of the position.

Top holdings aft the filing:
- NYSE:MS: $24.27 cardinal (15.6% of AUM)
- NASDAQ:AMZN: $15.30 cardinal (9.8% of AUM)
- NYSE:TEVA: $11.47 cardinal (7.4% of AUM)
- NYSE:NKE: $11.45 cardinal (7.4% of AUM)
- NYSE:ALC: $8.53 cardinal (5.5% of AUM)
As of Friday, Masimo shares were priced astatine $178.24, up astir 5% implicit the past year, compared to a 15% summation for the S&P 500.

Metric

Value

Price (as of Friday)	$178.24
Market capitalization	$9.6 billion
Revenue (TTM)	$1.5 billion
Net income (TTM)	($207.7 million)

Masimo develops and markets noninvasive diligent monitoring technologies, including pulse oximetry, encephalon relation monitoring, capnography, determination oximetry, and infirmary automation platforms.
The steadfast generates gross chiefly done nonstop sales, distributors, and OEM partnerships, offering some aesculapian and user wellness solutions.
It serves hospitals, exigency aesculapian services, location attraction providers, semipermanent attraction facilities, doc offices, veterinarians, and consumers globally.

Masimo is simply a starring supplier of precocious noninvasive monitoring technologies and infirmary automation solutions, with a planetary beingness and a absorption connected innovation successful diligent care. The institution leverages proprietary awesome extraction technologies to code captious needs successful healthcare monitoring, supporting objective decision-making and diligent safety. Its diversified merchandise portfolio and robust organisation channels presumption it arsenic a cardinal subordinate successful the aesculapian instruments and supplies industry.

This concern serves arsenic a reminder of however captious timing tin beryllium successful the banal market. The exit followed a lackluster quarter, with shares dipping astir 12%. While this driblet isn’t uncommon for a mid-cap medtech institution grappling with shifting merchandise cycles and adaptable infirmary spending, what transpired adjacent is what truly stands out. Just weeks later, Masimo announced an acquisition woody astatine $180 per share, totaling astir $9.9 billion, which propelled the banal upward by astir 34% successful 1 fell swoop.

It's successful that agelong betwixt determination and result wherever semipermanent investors request to support their focus. The portfolio remains heavy weighted toward large-cap, cash-generating giants similar Morgan Stanley and Amazon, alongside immoderate turnaround plays and healthcare stocks. This blend signals a penchant for stableness with a sprinkle of imaginable upside, but it besides leaves little country for those unsocial catalysts, specified arsenic mergers and acquisitions.

Masimo occupies a funny abstraction successful this mix. It’s not your emblematic speculative biotech, yet it inactive holds event-driven imaginable tied to strategical involvement and innovation trends. Selling into weakness whitethorn look logical erstwhile assurance wanes, but it besides risks cutting disconnected entree to precisely those asymmetrical opportunities that tin output important returns.

Read Entire Article